Contents

Search

tinzaparin (Innohep)

Tradename: Innohep. withdrawn from the U.S. market [5] (see low molecular weight heparin) Indications: - deep vein thrombosis (DVT)* - equivalent to warfarin for cancer patients with DVT [5] - pulmonary embolism* * equivalent to dalteparin Dosage: - 175 units/kg SC QD (full anticoagulation) Adverse effects: - increased mortality in patients > 70 with renal insufficiency [3] - see LMW heparin [4] Notes: Equivalent to dalteparin for treatment of: 1) deep vein thrombosis (DVT) 2) pulmonary embolism (PE)

Interactions

drug adverse effects of LMW heparin

General

low molecular weight (LMW) heparin

References

  1. Prescriber's Letter 7(12):72 2000 Detail-Document#: 161206 (subscription needed) http://www.prescribersletter.com
  2. Journal Watch 25(10):78, 2005 Wells PS, Anderson DR, Rodger MA, Forgie MA, Florack P, Touchie D, Morrow B, Gray L, O'Rourke K, Wells G, Kovacs J, Kovacs MJ. A randomized trial comparing 2 low-molecular-weight heparins for the outpatient treatment of deep vein thrombosis and pulmonary embolism. Arch Intern Med. 2005 Apr 11;165(7):733-8. PMID: 15824291
  3. FDA MedWatch http://www.fda.gov/medwatch/safety/2008/safety08.htm#Innohep
  4. Medical Knowledge Self Assessment Program (MKSAP) 16, American College of Physicians, Philadelphia 2012
  5. Lee AYY et al. Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: A randomized clinical trial. JAMA 2015 Aug 18; 314:677. PMID: 26284719